-
-
-
-
-
-
-
Ligand Reports Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators
-
-
-
-
-
-
-
Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
-
-
-
-
-
-
-
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
-
-
-
-
-
-
1,179,809 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

